ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AnaptysBio Inc (ANAB) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong technical indicators, positive analyst sentiment, and promising catalysts in its pipeline, despite some insider selling and recent financial challenges. The current price trend and long-term growth potential make it a suitable investment.
The technical indicators are bullish. The MACD histogram is positive and contracting, indicating upward momentum. The RSI is neutral at 70.068, and the moving averages (SMA_5 > SMA_20 > SMA_200) suggest a strong upward trend. The stock is trading near its resistance level of 57.012, with support at 54.789.
Analysts have raised price targets significantly, with Barclays increasing to $78 and UBS upgrading to Buy with a $70 target.
Positive clinical data for ANB033 and imsidolimab, showing strong efficacy and safety profiles.
Revenue growth of 154.26% YoY in Q3 2025, indicating strong top-line performance.
Upcoming earnings report on February 26, 2026, which could act as a catalyst.
Insiders have increased selling activity by 189.75% in the last month.
Net income and EPS have dropped significantly YoY, raising concerns about profitability.
No recent trading data from Congress or hedge funds to indicate strong institutional support.
In Q3 2025, revenue increased by 154.26% YoY to $76.32M, showing strong growth. However, net income dropped by 146.00% YoY to $15.11M, and EPS fell by 145.61% to 0.52, reflecting profitability challenges. Gross margin remained stable at 100%.
Analysts are bullish on ANAB, with multiple upgrades and raised price targets. Barclays increased the target to $78, UBS to $70, and Guggenheim to $140 following positive clinical data and pipeline developments. Despite some prior target reductions, the overall sentiment is optimistic for 2026.
